Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Bewersdorf JP, Kewan T, Lanino L, Wei W, Rudra Gupta T, Stempel JM, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Urrutia S, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Hawkins H, Chandhok NS, Logothetis CN, Bidikian A, Getz TM, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski JP, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta MG, Komrokji RS, Zeidan AM

Open source

DOI: 10.1038/s41408-026-01543-6
Published: 2026 Jun 29
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01543-6,
  title = {Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.},
  author = {Bewersdorf JP and Kewan T and Lanino L and Wei W and Rudra Gupta T and Stempel JM and Al Ali NH and DeZern AE and Sekeres MA and Uy GL and Urrutia S and Carraway HE and Desai P and Griffiths EA and Stein EM and Brunner AM and McMahon C and Shallis RM and Zeidner JF and Savona MR and Hawkins H and Chandhok NS and Logothetis CN and Bidikian A and Getz TM and Roboz GJ and Rolles B and Wang ES and Harris AC and Amaya ML and Ball S and Grenet J and Xie Z and Madanat YF and Abaza Y and Badar T and Campos J and Haferlach T and Maciejewski JP and Sallman D and Enjeti A and Al-Rabi K and Halahleh K and Hiwase D and Diez-Campelo M and Valcarcel D and Haferlach C and Pleyer L and Kotsianidis I and Pappa V and Santini V and Consagra A and Al-Kali A and Ogawa S and Nannya Y and Stahl M and Della Porta MG and Komrokji RS and Zeidan AM},
  year = {2026},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-026-01543-6},
  url = {https://doi.org/10.1038/s41408-026-01543-6}
}

RIS

TY  - JOUR
TI  - Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
AU  - Bewersdorf JP
AU  - Kewan T
AU  - Lanino L
AU  - Wei W
AU  - Rudra Gupta T
AU  - Stempel JM
AU  - Al Ali NH
AU  - DeZern AE
AU  - Sekeres MA
AU  - Uy GL
AU  - Urrutia S
AU  - Carraway HE
AU  - Desai P
AU  - Griffiths EA
AU  - Stein EM
AU  - Brunner AM
AU  - McMahon C
AU  - Shallis RM
AU  - Zeidner JF
AU  - Savona MR
AU  - Hawkins H
AU  - Chandhok NS
AU  - Logothetis CN
AU  - Bidikian A
AU  - Getz TM
AU  - Roboz GJ
AU  - Rolles B
AU  - Wang ES
AU  - Harris AC
AU  - Amaya ML
AU  - Ball S
AU  - Grenet J
AU  - Xie Z
AU  - Madanat YF
AU  - Abaza Y
AU  - Badar T
AU  - Campos J
AU  - Haferlach T
AU  - Maciejewski JP
AU  - Sallman D
AU  - Enjeti A
AU  - Al-Rabi K
AU  - Halahleh K
AU  - Hiwase D
AU  - Diez-Campelo M
AU  - Valcarcel D
AU  - Haferlach C
AU  - Pleyer L
AU  - Kotsianidis I
AU  - Pappa V
AU  - Santini V
AU  - Consagra A
AU  - Al-Kali A
AU  - Ogawa S
AU  - Nannya Y
AU  - Stahl M
AU  - Della Porta MG
AU  - Komrokji RS
AU  - Zeidan AM
PY  - 2026
JO  - Blood cancer journal
DO  - 10.1038/s41408-026-01543-6
UR  - https://doi.org/10.1038/s41408-026-01543-6
ER  -

APA

JP, B., T, K., L, L., W, W., T, R. G., JM, S., NH, A. A., AE, D., MA, S., GL, U., S, U., HE, C., P, D., EA, G., EM, S., AM, B., C, M., RM, S., JF, Z., MR, S., H, H., NS, C., CN, L., A, B., TM, G., GJ, R., B, R., ES, W., AC, H., ML, A., S, B., J, G., Z, X., YF, M., Y, A., T, B., J, C., T, H., JP, M., D, S., A, E., K, A., K, H., D, H., M, D., D, V., C, H., L, P., I, K., V, P., V, S., A, C., A, A., S, O., Y, N., M, S., MG, D. P., RS, K., & AM, Z. (2026). Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01543-6

Source records

pubmed · retrieved 2026-09-26T06:34:50.914Z
europe-pmc · retrieved 2026-09-26T06:34:50.933Z
doaj · retrieved 2026-09-26T06:34:50.914Z